Share on LinkedInShare on LinkedIn

ARTICLE · 09 MAY 2011

European IP Bulletin - Issue 79, April 2011

In "Gedeon Richter plc v Bayer Schering Pharma AG" [2011] EWHC 583 (Pat), Gedeon Richter plc applied to have two divisional patents belonging to Bayer Schering Pharma AG revoked for invalidity (the ‘301 and ‘069 patents).

European UnionIntellectual Property
Rohan Massey
Rohan Massey
Francesco Mattina
Francesco Mattina
Gary Moss
Gary Moss
Vincent Schröder
Vincent Schröder
Hiroshi Sheraton
Hiroshi Sheraton
Boris Uphoff
Boris Uphoff
Author LinkedIn connections

PATENTS

Gedeon Richter plc v Bayer Schering Pharma AG: "Obvious to Try" and "Fair Expectation of Success"

In Gedeon Richter plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat), Gedeon Richter plc applied to have two divisional patents belonging to Bayer Schering Pharma AG revoked for invalidity (the '301 and '069 patents). One of the grounds of invalidity was that the patents were obvious in respect of four items of prior art.

The patents were for the combination of two steroidal hormones, ethinylestradiol (EE) and drospirenone (DSP), both of which regulate the female menstrual cycle and are used as a contraceptive. Both patents under examination were aimed at finding an effective and safe formulation of the hormones in the development of an oral contraceptive pill. They were directed towards a skilled formulation team working specifically in the area of the development of oral contraceptives.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from